---
document_datetime: 2025-12-02 05:24:08
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/toujeo.html
document_name: toujeo.html
version: success
processing_time: 0.1410645
conversion_datetime: 2025-12-23 21:36:30.741081
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Toujeo (previously Optisulin)

[RSS](/en/individual-human-medicine.xml/66002)

##### Authorised

This medicine is authorised for use in the European Union

insulin glargine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Toujeo (previously Optisulin)](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-77890)
- [Preventing medication errors](#preventing-medication-errors-1170)
- [More information on Toujeo (previously Optisulin)](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Toujeo is a medicine used to control blood glucose (sugar) levels in adults and children from 6 years of age who have diabetes and need insulin.

It contains the active substance insulin glargine.

Expand section

Collapse section

## How is Toujeo used?

Toujeo is available as prefilled pens containing a solution for injection of 300 units/ml. It is injected once a day under the skin in the abdominal wall (tummy), the thigh, or the deltoid region (shoulder). The site of injection should be changed with each injection to avoid changes to the skin (such as thickening) that would change the way the insulin is absorbed. The patient's blood glucose should be regularly tested to find the lowest effective dose.

Toujeo 300 units/ml must not be used interchangeably with the lower strength insulin glargine (100 units/ml).

The medicine can only be obtained with a prescription. For more information about using Toujeo, see the package leaflet or contact your doctor or pharmacist.

## How does Toujeo work?

Diabetes is a disease in which the body does not produce enough insulin to control the level of blood glucose. Toujeo is a replacement insulin that is very similar to the insulin made by the body.

The active substance in Toujeo, insulin glargine, is slightly different from human insulin. The difference means that it is absorbed more slowly and regularly by the body after an injection, and that it has a long duration of action. The replacement insulin acts in the same way as naturally produced insulin and helps glucose enter cells from the blood. By controlling the level of blood glucose, the symptoms and complications of diabetes are reduced.

## What benefits of Toujeo have been shown in studies?

The company submitted studies carried out with insulin glargine 100 units/ml.

In addition, the effects of Toujeo were compared with those of insulin glargine 100 units/ml in 4 studies involving 3,045 adults with either type 1 diabetes (when the pancreas cannot produce insulin) or type 2 diabetes (when the body is unable to use insulin effectively). In these studies, Toujeo 300 units/ml was comparable to insulin glargine (100 units/ml) at controlling blood glucose levels.

Toujeo was also comparable to insulin glargine 100 units/ml at controlling blood glucose levels in a study involving 463 children and adolescents aged 6 to 17 years who had type 1 diabetes.

## What are the risks associated with Toujeo?

The most common side effect with Toujeo (seen in more than 1 patient in 10) is hypoglycaemia (low blood glucose levels). Reactions at the site of the injection (redness, pain, itching and swelling) and skin reactions (rash) have been seen more often in children than in adults.

For the full list of side effects and restrictions with Toujeo, see the package leaflet.

## Why is Toujeo authorised in the EU?

The European Medicines Agency decided that Toujeo's benefits are greater than its risks and it can be authorised for use in the EU.

The benefits and safety of insulin glargine in controlling blood glucose level are well established and use of Toujeo allows for a smaller volume to be injected compared with standard insulin, which may be important for patients who require large amounts of insulin.

## What measures are being taken to ensure the safe and effective use of Toujeo?

The company that markets Toujeo will provide educational material to healthcare professionals aimed particularly at raising awareness that Toujeo contains insulin that is of a higher strength than standard insulin. The company will also produce educational material for patients on how to use Toujeo correctly, which they should receive from their doctor together with suitable training.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Toujeo have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Toujeo are continuously monitored. Side effects reported with Toujeo are carefully evaluated and any necessary action taken to protect patients.

## Other information about Toujeo

Toujeo received a marketing authorisation valid throughout the EU on 27 June 2000.

Toujeo : EPAR - Medicine overview

Reference Number: EMA/598962/2019

English (EN) (129.7 KB - PDF)

**First published:** 11/05/2009

**Last updated:** 03/12/2019

[View](/en/documents/overview/toujeo-epar-medicine-overview_en.pdf)

Toujeo : EPAR - Risk Management Plan Summary

English (EN) (185.72 KB - PDF)

**First published:** 09/08/2023

[View](/en/documents/rmp-summary/toujeo-epar-risk-management-plan-summary_en.pdf)

## Product information

Toujeo : EPAR - Product Information

English (EN) (1.31 MB - PDF)

**First published:** 11/05/2009

**Last updated:** 09/07/2025

[View](/en/documents/product-information/toujeo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-859)

български (BG) (1.46 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/bg/documents/product-information/toujeo-epar-product-information_bg.pdf)

español (ES) (1.4 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/es/documents/product-information/toujeo-epar-product-information_es.pdf)

čeština (CS) (1.6 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/cs/documents/product-information/toujeo-epar-product-information_cs.pdf)

dansk (DA) (1.3 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/da/documents/product-information/toujeo-epar-product-information_da.pdf)

Deutsch (DE) (1.67 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/de/documents/product-information/toujeo-epar-product-information_de.pdf)

eesti keel (ET) (1.23 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/et/documents/product-information/toujeo-epar-product-information_et.pdf)

ελληνικά (EL) (1.8 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/el/documents/product-information/toujeo-epar-product-information_el.pdf)

français (FR) (1.7 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/fr/documents/product-information/toujeo-epar-product-information_fr.pdf)

hrvatski (HR) (1.09 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/hr/documents/product-information/toujeo-epar-product-information_hr.pdf)

íslenska (IS) (1.43 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/is/documents/product-information/toujeo-epar-product-information_is.pdf)

italiano (IT) (1.79 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/it/documents/product-information/toujeo-epar-product-information_it.pdf)

latviešu valoda (LV) (1.53 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/lv/documents/product-information/toujeo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.52 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/lt/documents/product-information/toujeo-epar-product-information_lt.pdf)

magyar (HU) (1.73 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/hu/documents/product-information/toujeo-epar-product-information_hu.pdf)

Malti (MT) (1.76 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/mt/documents/product-information/toujeo-epar-product-information_mt.pdf)

Nederlands (NL) (1.34 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/nl/documents/product-information/toujeo-epar-product-information_nl.pdf)

norsk (NO) (1.72 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/no/documents/product-information/toujeo-epar-product-information_no.pdf)

polski (PL) (1.7 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/pl/documents/product-information/toujeo-epar-product-information_pl.pdf)

português (PT) (1.39 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/pt/documents/product-information/toujeo-epar-product-information_pt.pdf)

română (RO) (1.74 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/ro/documents/product-information/toujeo-epar-product-information_ro.pdf)

slovenčina (SK) (1.49 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/sk/documents/product-information/toujeo-epar-product-information_sk.pdf)

slovenščina (SL) (1.53 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/sl/documents/product-information/toujeo-epar-product-information_sl.pdf)

Suomi (FI) (1.32 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/fi/documents/product-information/toujeo-epar-product-information_fi.pdf)

svenska (SV) (1.38 MB - PDF)

**First published:**

11/05/2009

**Last updated:**

09/07/2025

[View](/sv/documents/product-information/toujeo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000266075 09/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Toujeo : EPAR - All Authorised presentations

English (EN) (51.61 KB - PDF)

**First published:** 11/05/2009

**Last updated:** 23/07/2019

[View](/en/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-405)

български (BG) (71.57 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/bg/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_bg.pdf)

español (ES) (23.94 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/es/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (83.76 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/cs/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (25.23 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/da/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (91.68 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/de/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (31.02 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/et/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (107.28 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/el/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_el.pdf)

français (FR) (27.14 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/fr/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (33.04 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/hr/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (46.65 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/is/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (29.04 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/it/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (46.7 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/lv/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (50.46 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/lt/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (49.67 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/hu/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (69.56 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/mt/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (24.57 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/nl/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (23.07 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/no/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_no.pdf)

polski (PL) (58.45 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/pl/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_pl.pdf)

português (PT) (27.72 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/pt/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_pt.pdf)

română (RO) (46.26 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/ro/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (52.5 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/sk/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (32.99 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/sl/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (87.44 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/fi/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (27.77 KB - PDF)

**First published:**

11/05/2009

**Last updated:**

23/07/2019

[View](/sv/documents/all-authorised-presentations/toujeo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Toujeo (previously Optisulin) Active substance insulin glargine International non-proprietary name (INN) or common name insulin glargine Therapeutic area (MeSH) Diabetes Mellitus Anatomical therapeutic chemical (ATC) code A10AE04

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

Treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years.

## Authorisation details

EMA product number EMEA/H/C/000309 Marketing authorisation holder

Sanofi-aventis Deutschland GmbH

D-65926 Frankfurt am Main

Opinion adopted 17/02/2000 Marketing authorisation issued 26/06/2000 Revision 37

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Toujeo : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (142.17 KB - PDF)

**First published:** 09/07/2025

[View](/en/documents/procedural-steps-after/toujeo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Toujeo : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (305.06 KB - PDF)

**First published:** 11/05/2009

**Last updated:** 09/07/2025

[View](/en/documents/procedural-steps-after/toujeo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Toujeo-H-C-309-PSUSA-1751-201904 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/56836/2020

English (EN) (189.32 KB - PDF)

**First published:** 04/02/2020

[View](/en/documents/scientific-conclusion/toujeo-h-c-309-psusa-1751-201904-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Toujeo-H-C-309-II-0108 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/596054/2019

English (EN) (1.67 MB - PDF)

**First published:** 03/12/2019

[View](/en/documents/variation-report/toujeo-h-c-309-ii-0108-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Toujeo (II-108)

Adopted

Reference Number: EMA/CHMP/571247/2019

English (EN) (113.62 KB - PDF)

**First published:** 18/10/2019

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-toujeo-ii-108_en.pdf)

Toujeo-H-C-309-P46-051.1 : EPAR - Assessment Report

Adopted

Reference Number: EMA/308852/2015

English (EN) (292.15 KB - PDF)

**First published:** 18/05/2015

**Last updated:** 18/05/2015

[View](/en/documents/variation-report/toujeo-h-c-309-p46-0511-epar-assessment-report_en.pdf)

Toujeo-H-C-309-X-0079-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/157145/2015

English (EN) (1.02 MB - PDF)

**First published:** 07/05/2015

**Last updated:** 07/05/2015

[View](/en/documents/variation-report/toujeo-h-c-309-x-0079-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Toujeo

Adopted

Reference Number: EMA/CHMP/124102/2015

English (EN) (69.62 KB - PDF)

**First published:** 27/02/2015

**Last updated:** 27/02/2015

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-toujeo_en.pdf)

Optisulin-H-C-309-II-0064 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/439632/2012

English (EN) (1.14 MB - PDF)

**First published:** 28/08/2012

**Last updated:** 28/08/2012

[View](/en/documents/variation-report/optisulin-h-c-309-ii-0064-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Optisulin

Adopted

Reference Number: EMA/CHMP/184676/2012

English (EN) (49.82 KB - PDF)

**First published:** 20/04/2012

**Last updated:** 20/04/2012

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-optisulin_en.pdf)

Optisulin : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (82.04 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/steps-after-cutoff/optisulin-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Optisulin : EPAR - Procedural steps taken before authorisation

English (EN) (97.89 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/procedural-steps/optisulin-epar-procedural-steps-taken-authorisation_en.pdf)

Optisulin : EPAR - Scientific Discussion

English (EN) (215.88 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/scientific-discussion/optisulin-epar-scientific-discussion_en.pdf)

#### News on Toujeo (previously Optisulin)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-october-2019) 18/10/2019

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 February 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-february-2015) 27/02/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2013) 31/05/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 April 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-april-2012) 20/04/2012

[European Medicines Agency update on safety of insulin glargine - Update](/en/news/european-medicines-agency-update-safety-insulin-glargine-update) 29/07/2009

[European Medicines Agency update on safety of insulin glargine](/en/news/european-medicines-agency-update-safety-insulin-glargine) 29/06/2009

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Toujeo : EPAR - Product information - tracked changes

English (EN) (2.09 MB - DOCX)

**First published:** 09/07/2025

[View](/en/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-315)

български (BG) (1.93 MB - DOCX)

**First published:**

09/07/2025

[View](/bg/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_bg.docx)

español (ES) (2.24 MB - DOCX)

**First published:**

09/07/2025

[View](/es/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_es.docx)

čeština (CS) (2.48 MB - DOCX)

**First published:**

09/07/2025

[View](/cs/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (1.65 MB - DOCX)

**First published:**

09/07/2025

[View](/da/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (2.29 MB - DOCX)

**First published:**

09/07/2025

[View](/de/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (1.54 MB - DOCX)

**First published:**

09/07/2025

[View](/et/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (2.54 MB - DOCX)

**First published:**

09/07/2025

[View](/el/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_el.docx)

français (FR) (2.22 MB - DOCX)

**First published:**

09/07/2025

[View](/fr/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (1.9 MB - DOCX)

**First published:**

09/07/2025

[View](/hr/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (2.31 MB - DOCX)

**First published:**

09/07/2025

[View](/is/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_is.docx)

italiano (IT) (2.31 MB - DOCX)

**First published:**

09/07/2025

[View](/it/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (2.57 MB - DOCX)

**First published:**

09/07/2025

[View](/lv/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (2.22 MB - DOCX)

**First published:**

09/07/2025

[View](/lt/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (2.08 MB - DOCX)

**First published:**

09/07/2025

[View](/hu/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (1.81 MB - DOCX)

**First published:**

09/07/2025

[View](/mt/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (2.23 MB - DOCX)

**First published:**

09/07/2025

[View](/nl/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (2.31 MB - DOCX)

**First published:**

09/07/2025

[View](/no/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_no.docx)

polski (PL) (1.98 MB - DOCX)

**First published:**

09/07/2025

[View](/pl/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_pl.docx)

português (PT) (2.26 MB - DOCX)

**First published:**

09/07/2025

[View](/pt/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_pt.docx)

română (RO) (2.24 MB - DOCX)

**First published:**

09/07/2025

[View](/ro/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (3.06 MB - DOCX)

**First published:**

09/07/2025

[View](/sk/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (2.37 MB - DOCX)

**First published:**

09/07/2025

[View](/sl/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (2.09 MB - DOCX)

**First published:**

09/07/2025

[View](/fi/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (2.27 MB - DOCX)

**First published:**

09/07/2025

[View](/sv/documents/product-information-tracked-changes/toujeo-epar-product-information-tracked-changes_sv.docx)

#### Preventing medication errors

Insulins (high-strength): guidance on prevention of medication errors

Reference Number: EMA/134145/2015

English (EN) (81.81 KB - PDF)

**First published:** 27/11/2015

**Last updated:** 27/11/2015

[View](/en/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_en.pdf)

[Other languages (21)](#file-language-dropdown-763)

español (ES) (87.17 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/11/2015

[View](/es/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_es.pdf)

čeština (CS) (107.44 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/11/2015

[View](/cs/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_cs.pdf)

dansk (DA) (86.01 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/11/2015

[View](/da/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_da.pdf)

Deutsch (DE) (89.16 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/11/2015

[View](/de/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_de.pdf)

eesti keel (ET) (86.12 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/11/2015

[View](/et/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_et.pdf)

ελληνικά (EL) (115.63 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/11/2015

[View](/el/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_el.pdf)

français (FR) (88.53 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/11/2015

[View](/fr/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_fr.pdf)

hrvatski (HR) (105.58 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/11/2015

[View](/hr/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_hr.pdf)

italiano (IT) (87.73 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/11/2015

[View](/it/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_it.pdf)

latviešu valoda (LV) (108.71 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/11/2015

[View](/lv/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_lv.pdf)

lietuvių kalba (LT) (108.79 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/11/2015

[View](/lt/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_lt.pdf)

magyar (HU) (108.4 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/11/2015

[View](/hu/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_hu.pdf)

Malti (MT) (111.45 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/11/2015

[View](/mt/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_mt.pdf)

Nederlands (NL) (87.33 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/11/2015

[View](/nl/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_nl.pdf)

polski (PL) (109.39 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/11/2015

[View](/pl/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_pl.pdf)

português (PT) (87.88 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/11/2015

[View](/pt/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_pt.pdf)

română (RO) (109.94 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/11/2015

[View](/ro/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_ro.pdf)

slovenčina (SK) (107.89 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/11/2015

[View](/sk/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_sk.pdf)

slovenščina (SL) (104.26 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/11/2015

[View](/sl/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_sl.pdf)

Suomi (FI) (86.21 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/11/2015

[View](/fi/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_fi.pdf)

svenska (SV) (87.24 KB - PDF)

**First published:**

27/11/2015

**Last updated:**

27/11/2015

[View](/sv/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_sv.pdf)

Outcome of review of new safety data on insulin glargine

Reference Number: EMA/329790/2013

English (EN) (98.14 KB - PDF)

**First published:** 31/05/2013

**Last updated:** 31/05/2013

[View](/en/documents/medicine-qa/outcome-review-new-safety-data-insulin-glargine_en.pdf)

#### More information on Toujeo (previously Optisulin)

- [Insulin glargine - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/insulin-glargine-0)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 09/07/2025

## Share this page

[Back to top](#main-content)